Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 02, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial)".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 02, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial)".